{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:55:35Z","timestamp":1790916935887,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Urol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>5-alpha-reductase inhibitors (5-ARIs), such as finasteride and dutasteride, are effective in reducing prostate volume and urinary symptoms; however, these drugs are associated with specific adverse events, including suicidal ideation, anxiety, and self-harm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis of observational studies was conducted in PubMed, Embase and Web of Science on July 16, 2025, with no time restrictions. Studies involved individuals diagnosed with benign prostatic hyperplasia (BPH) or androgenetic alopecia (AGA), and experiencing suicide and neuropsychiatric events, including anxiety, depression and intentional self-harm (ISH) during the treatment with 5-ARIs. This study followed the PRISMA statement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven studies were included in the systematic review, of which nine were eligible for meta-analysis. Comparisons included 5-ARI users versus non-users or alpha-blocker users. Overall, no statistically significant differences were observed between groups (HR 1.07, 95% CI: 0.76\u20131.51), with substantial heterogeneity across studies (I\u00b2 = 59%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis found no significant association between 5-ARIs and the risk of suicide or neuropsychiatric events in patients with benign prostatic hyperplasia or androgenetic alopecia. Nevertheless, given regulatory concerns regarding suicidal ideation, continued real-world monitoring through active surveillance and prospective observational studies remain warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251106035<\/jats:ext-link>\n                      , identifier CRD420251106035.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fruro.2026.1881635","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:36:44Z","timestamp":1790915804000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["5-\u03b1-reductase inhibitors and the risk of suicide and neuropsychiatric symptoms: a meta-analysis of observational studies"],"prefix":"10.3389","volume":"6","author":[{"given":"Federica","family":"Fraenza","sequence":"first","affiliation":[{"name":"Department of Experimental Medicine, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]},{"name":"Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Liguori","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]},{"name":"Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Pentella","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]},{"name":"Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consiglia","family":"Riccardi","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]},{"name":"Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Futura","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Coordination of the Regional Health System, General Directorate for Health Protection, Department of Experimental Medicine, University of Campania Luigi Vanvitelli","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]},{"name":"Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Scavone","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]},{"name":"Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]},{"name":"Department of Life Science, Health, and Health Professions, Link Campus University","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","article-title":"Finasteride","volume-title":"Statpearls","author":"Zito","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030330","article-title":"Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor","volume":"89","author":"Clark","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.813011","article-title":"The efficacy and safety of 5\u03b1-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride","volume":"25","author":"Gupta","year":"2014","journal-title":"J Dermatol Treat"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21037\/tau-22-58","article-title":"The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"11","author":"Li","year":"2022","journal-title":"Trans andrology Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.007","article-title":"The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride","volume":"55","author":"Olsen","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5021\/ad.22.027","article-title":"Long-term effectiveness and safety of dutasteride versus finasteride in patients with male androgenic alopecia in South Korea: a multicentre chart review study","volume":"34","author":"Choi","year":"2022","journal-title":"Ann Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112100","article-title":"The connection of 5-alpha reductase inhibitors to the development of depression","volume":"143","author":"Saengmearnuparp","year":"2021","journal-title":"Biomedicine Pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"B8","unstructured":"Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines"},{"key":"B9","unstructured":"Finasteride- and dutasteride-containing medicinal products \u2013 referral"},{"key":"B10","unstructured":"Measures to minimize the risk of suicidal thoughts with finasteride, dutasteride drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Res Ed)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.09.018","article-title":"GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence-an overview in the context of health decision-making","volume":"129","author":"Brozek","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"10962","DOI":"10.1038\/s41598-025-95583-w","article-title":"Differential association between cumulative dose of 5\u03b1-reductase inhibitors and mortality","volume":"15","author":"Kim","year":"2025","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.0089","article-title":"Association of suicidality and depression with 5\u03b1-reductase inhibitors","volume":"177","author":"Welk","year":"2017","journal-title":"JAMA Intern Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2024.06.013","article-title":"Suicide and intentional self-harm among older men treated with 5-alpha reductase inhibitor or alpha-blockers for benign prostatic hyperplasia","volume":"192","author":"Pennap","year":"2024","journal-title":"Urology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0000000000000784","article-title":"The association of 5\u03b1-reductase inhibitor with suicidality","volume":"82","author":"Kim","year":"2020","journal-title":"Psychosomatic Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265169","article-title":"Depression risk associated with the use of 5\u03b1-reductase inhibitors versus \u03b1-blockers: a retrospective cohort study in South Korea","volume":"17","author":"Yeon","year":"2022","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1925","article-title":"Risk of incident antidepressant-treated depression associated with use of 5\u03b1-reductase inhibitors compared with use of \u03b1-blockers in men with benign prostatic hyperplasia: a population-based study using the Clinical Practice Research Datalink","volume":"37","author":"Hagberg","year":"2017","journal-title":"Pharmacotherapy"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14359","article-title":"The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia and androgenetic alopecia: a population-based case-control study","volume":"65","author":"Lyakhovitsky","year":"2024","journal-title":"Australas J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.48135","article-title":"Association of 5\u03b1-reductase inhibitors with dementia, depression, and suicide","volume":"5","author":"Garcia-Argibay","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/pds.671","article-title":"Drug or symptom-induced depression in men treated with alpha 1-blockers for benign prostatic hyperplasia? A nested case-control study","volume":"11","author":"Clifford","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1038\/s41598-023-32356-3","article-title":"Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study","volume":"13","author":"Laanani","year":"2023","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2016.28.4.4442","article-title":"Safety and tolerability of the dual 5-alpha reductase inhibitor dutasteride in the treatment of androgenetic alopecia","volume":"28","author":"Choi","year":"2016","journal-title":"Ann Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2012.02846.x","article-title":"Persistent sexual side effects of finasteride for male pattern hair loss","volume":"9","author":"Irwig","year":"2012","journal-title":"J Sexual Med."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2010.02157.x","article-title":"Adverse side effects of 5\u03b1-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients","volume":"8","author":"Traish","year":"2011","journal-title":"J Sexual Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2019.100209","article-title":"Post-finasteride syndrome: an emerging clinical problem","volume":"12","author":"Diviccaro","year":"2019","journal-title":"Neurobiol Stress"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0199","article-title":"Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study","volume":"8","author":"Melcangi","year":"2019","journal-title":"Endocrine Connections"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2011.02255.x","article-title":"Persistent sexual side effects of finasteride for male pattern hair loss","volume":"11","author":"Irwig","year":"2014","journal-title":"J Sexual Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.04.009","article-title":"Association of 5\u03b1-reductase inhibitors with depression and suicide: a mini systematic review and meta-analysis","volume":"10","author":"Uleri","year":"2024","journal-title":"Eur Urol Focus"},{"key":"B31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12894-018-0368-x","article-title":"Daily tadalafil for the chronic phase of stuttering priapism: a case report","volume":"18","author":"Massenio","year":"2018","journal-title":"BMC Urol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00345-024-05127-6","article-title":"UroLift to preserve seminal parameters in young male with LUTS from BPH","volume":"42","author":"Annese","year":"2024","journal-title":"World J Urol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.12.038","article-title":"EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction","volume":"67","author":"Gratzke","year":"2015","journal-title":"Eur Urol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.21037\/tau-22-92","article-title":"Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients","volume":"11","author":"Li","year":"2022","journal-title":"Trans andrology Urol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-023-00759-5","article-title":"The post-finasteride syndrome: possible etiological mechanisms and symptoms","volume":"37","author":"Leliefeld","year":"2025","journal-title":"Int J Impotence Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-024-00668-4","article-title":"Safety of dapagliflozin and empagliflozin in cases with diabetes mellitus or\/and heart failure: a retrospective pharmacovigilance study conducted on the eudravigilance database","volume":"77","author":"Mascolo","year":"2025","journal-title":"Pharmacol Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-025-00725-6","article-title":"Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data","volume":"77","author":"Balzano","year":"2025","journal-title":"Pharmacol Rep Pr"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.230327","article-title":"Comparison of finasteride and dutasteride on risk of prostate cancer in patients with benign prostatic hyperplasia: a pooled analysis of 15 real-world databases","volume":"43","author":"Yang","year":"2025","journal-title":"World J Men's Health"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Urology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1881635\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:36:51Z","timestamp":1790915811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1881635\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":39,"alternative-id":["10.3389\/fruro.2026.1881635"],"URL":"https:\/\/doi.org\/10.3389\/fruro.2026.1881635","relation":{},"ISSN":["2673-9828"],"issn-type":[{"value":"2673-9828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1881635"}}